- Supported exchanges /
- F /
- B1N0.F
BIONOMICS ADR/1/180 (B1N0 F) stock market data APIs
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
BIONOMICS ADR/1/180 Financial Data Overview
| 0.282 | |
| 0.282 | |
| - | |
| 0.282 | |
| 0.282 | |
| 0.0805-2.18 | |
| 11 001 K | |
| 17 320 K | |
| 662 K | |
| -0.162 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BIONOMICS ADR/1/180 Fundamental Data is available in our Financial Data APIs
- Net Revenue 662 K
- EBITDA -17 351 144
- Earnings Per Share -1.66
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get BIONOMICS ADR/1/180 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get BIONOMICS ADR/1/180 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
